Your Cart Is Empty!
Global Markets Directs, Colon Cancer - Pipeline Review, H2 2015, provides an overview of the Colon Cancers therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Aduro BioTech, Inc.
Advanced Proteome Therapeutics Corporation
Advenchen Laboratories, LLC
AGV Discovery, SAS
AIMM Therapeutics B.V.
Alethia Biotherapeutics Inc.
Anavex Life Sciences Corp.
ANP Technologies, Inc.
Aptose Biosciences Inc.
Astex Pharmaceuticals, Inc.
Aurigene Discovery Technologies Limited
Bio-Path Holdings, Inc.
Bioncotech Therapeutics S.L.
Caladrius Biosciences, Inc.
Can-Fite BioPharma Ltd.
Carna Biosciences, Inc.
Critical Outcome Technologies Inc.
CureFAKtor Pharmaceuticals, LLC
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
Cytune Pharma SAS
CZ BioMed Corp
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
GlycaNova Norway AS
HanAll Biopharma Co., Ltd.
Heat Biologics, Inc.
Helix BioPharma Corp.
Horizon Pharma Plc
Idera Pharmaceuticals, Inc.
IMPACT Therapeutics, Inc.
Infinity Pharmaceuticals, Inc.
Inflection Biosciences Limited
Ironwood Pharmaceuticals, Inc.
Jasco Pharmaceuticals, LLC.
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
Lymphocyte Activation Technologies, S.A.
MabVax Therapeutics Holdings, Inc.
Millennium Pharmaceuticals, Inc.
Molecular Targeting Technologies, Inc.
Monopar Therapeutics LLC
Omnitura Therapeutics Inc.
Oncology Research International Limited
OncoVista Innovative Therapies, Inc.
Ono Pharmaceutical Co., Ltd.
Orega Biotech SAS
OSE Pharma SA
Panacea Pharmaceuticals, Inc.
Panacela Labs, Inc.
PharmaCyte Biotech, Inc.
Phosplatin Therapeutics LLC
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Qu Biologics Inc.
Regeneron Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
Sareum Holdings Plc
Savoy Pharmaceuticals, Inc.
Sorrento Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Starpharma Holdings Limited
Synta Pharmaceuticals Corp.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Transgene Biotek Limited
TVAX Biomedical, Inc.
Tyg Oncology Ltd.
Verlyx Pharma Inc.
Virocan Therapeutics Private Limited
Yakult Honsha Co., Ltd.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.